- Research Article
- 10.15581/009.10.30415
Articulación de la «filosofía trascendental» de Fichte
- Oct 22, 2018
- Anuario Filosófico
- Juan Cruz Cruz
Publications from 2021 to 2026
Showing 4 of 4 papers
Articulación de la «filosofía trascendental» de Fichte
Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy
Rotation thromboelastometry (ROTEM) is a viscoelastometric point-of-care-test for the complex evaluation of changes in hemostasis, performed in whole blood. However, no prospective study evaluating the efficacy of the antiplatelet therapy using ROTEM was performed.Fifty-six patients (34 men, 22 women, mean age 67.75 years, and age range 34–88 years) with acute ST-elevation myocardial infarction (STEMI), treated with dual antiplatelet therapy, undergoing urgent coronary angiography and percutaneous coronary intervention (PCI) of culprit coronary lesion were included. Three blood samples were taken (sample 1 taken before the urgent coronary angiography, sample 2 in 24 hours after the admission, and sample 3 in 30 days after acute STEMI). Twenty-one healthy blood donors (17 men, 4 women, mean age 50.38 years, and age range 40–74 years) were recruited as the control group. Blood samples were tested with ROTEM Gamma (Pentapharm GmbH, Munich, Germany) and light transmission aggregometry (LTA).Clotting time (CT) was significantly prolonged and maximum clot firmness (MCF) was significantly higher in patients compared to controls. Mean platelet aggregation after the induction with arachidonic acid (33.2% vs 74.6% in sample 1 and 21.1% vs 74.6% in sample 2), as well as adenosine diphosphate (51.4% vs 72.7% in sample 1 and 37.1% vs 72.7% in sample 2), were significantly lower in patients with acute STEMI.Significantly prolonged CT and increased MCF was found in patients with acute STEMI. This study confirmed the ability of ROTEM to identify changes in hemostasis in ACS patients on antithrombotic therapy.
Read moreAnalysis of the expression of platelet antigens CD9 and CD41/61 in transgenic rabbits with the integrated human blood clotting factor VIII gene construct
The objective of this research was to study the expression of cell membrane molecules CD9 and CD41/61 of transgenic rabbit with integrated human factor VIII (rhFVIII) gene construct. The expressions of these molecules have been monitored during two lactations of transgenic rabbits and simultaneously compared with the expression of the same molecules of non-transgenic rabbits. The immunochemical analysis by indirect immunofluorescence, ELISA and indirect immunoperoxidase staining of blood cells and udder tissues show that the insertion of the WAP-hFVIII gene construct into the rabbit genome, do not influence the expression of cell membrane antigens CD9 and CD41/61 on the blood platelets, polymorphonuclear blood cells, milk somatic cells and mammary gland tissues.
Read moreIdentification of bovine CD52-like molecule by monoclonal antibody IVA-543: distribution of CD52-like molecule in the bull genital tract